dihydroartemisinin

^[1]

Indications

* used in combination with piperaquine (had been 1st line southeast Asia)

* resistance to combination first observed in Cambodia in 2008^[1]

* in 2018, > 80% of Plasmodium falciparum in some regions in Southeast Asia resistant

↑ ^1.0 ^1.1 Hamilton WL, Amato R, van der Pluijm RW et al Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases. July 22, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31345709 Free Article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30392-5/fulltext
van der Pluijm RW, Imwong M, Chau NH et al Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases. July 22, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31345710 Free Article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30391-3/fulltext
Menard D, Fidock DA Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infectious Diseases. July 22, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31345711 Free Article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30394-9/fulltext